Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Development of a thick and functional human adipose-derived stem cell tissue sheet for myocardial infarction repair in rat hearts.

Zhang J., Li J., Qu X., Liu Y., Harada A., Hua Y.

Clinical Trial on Cardiovascular Disease, Scar, published in Stem Cell Res Ther (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Res Ther (2023)
Country
England
Reported sample size
—
Source database
PubMed
PMID
38124195
PMCID
PMC10734106
DOI
10.1186/s13287-023-03560-9
Citations
11

Abstract (original English)

Background Heart failure (HF) is a major cause of death worldwide. The most effective treatment for HF is heart transplantation, but its use is limited by the scarcity of donor hearts. Recently, stem cell-based therapy has emerged as a promising approach for treating myocardial infarction. Our research group has been investigating the use of human induced pluripotent stem cell-derived cardiomyocyte patches as a potential therapeutic candidate. We have successfully conducted eight cases of clinical trials and demonstrated the safety and effectiveness of this approach. However, further advancements are necessary to overcome immune rejection and enhance therapeutic efficacy. In this study, we propose a novel and efficient technique for constructing mesenchymal stem cell (MSC) tissue sheets, which can be transplanted effectively for treating myocardial infarction repair. Methods We applied a one-step method to construct the human adipose-derived mesenchymal stem cell (hADSC) tissue sheet on a poly(lactic-co-glycolic acid) fiber scaffold. Histology, immunofluorescence, and paracrine profile assessment were used to determine the organization and function of the hADSC tissue sheet. Echocardiography and pathological analyses of heart sections were performed to evaluate cardiac function, fibrosis area, angiogenesis, and left ventricular remodeling. Results In vitro, the hADSC tissue she

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansRatsAnimalsHeart TransplantationMesenchymal Stem Cell TransplantationInduced Pluripotent Stem CellsTissue DonorsMyocardial InfarctionHeart FailureFibrosis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research